Cocrystal Pharma Inc. announced the company has selected its broad-spectrum 3CL protease inhibitor CDI-988 for development as a potential oral therapy for norovirus.
Celmatix Inc. and Aché Laboratórios Farmacéuticos SA will study the role of melatonin receptors and their agonists in polycystic ovary syndrome (PCOS). The two companies announced a collaboration, with a separate license and development agreement upon conclusion of the research.
Researchers from University of Toronto and affiliated organizations have presented the discovery and preclinical evaluation of novel inhibitors of fungal fatty acid biosynthesis as potential antifungal agents. High-throughput screening of a library of natural products against representative isolates of four major human pathogenic yeast species (Candida albicans, C. glabrata, C. auris, C. neoformans) resulted in the discovery of the triazenyl indole NPD-6433.
An experimental vaccine that contained antigens of both lytic and latent phases of Epstein-Barr virus (EBV), and induced both an antibody and a T cells response, was able to generate broad and long-lasting immunity against EBV in mouse models of infection. Researchers from the QIMR Berghofer Medical Research Institute and Elicio Therapeutics Inc. reported those results online in Nature Communications on Aug. 8, 2023.
For some viruses, the challenge to developing a vaccine is their rapid mutation rate. This is the major challenge to developing an HIV vaccine or a universal flu vaccine. EBV is different. Its superpower is its ability to hide.
AGV Discovery SAS, in collaboration with scientists from Centre National de la Recherche Scientifique, Inserm and Universite de Montpellier, divulged azaindole derivatives acting as extracellular-regulated kinase (ERK) inhibitors, particularly ERK2, reported to be useful for the treatment of cancer, inflammation, autoimmune disease, substance abuse and dependence, metabolic syndrome, neurodegeneration, HIV infection, and pain, among other disorders.
Shenzhen Salubris Pharmaceuticals Co. Ltd. has described integrin α4β7 (LPAM-1) antagonists reported to be useful for the treatment of gastroenteritis.
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed MAP kinase-activated protein kinase 2 (MK2) inhibitors reported to be useful for the treatment of cancer, inflammatory disorders, atherosclerosis, diabetes and fibrosis, as well as metabolic and autoimmune diseases.
Dong Wha Pharmaceutical Co. Ltd. has defined histone-lysine N-methyltransferase EZH1 and/or EZH2 inhibitors reported to be useful for the treatment of cancer.
Gri Bio Inc. reported data on its type 2 natural killer T (NKT) cell activator GRI-0803 at the Autoimmunity Conference hosted by FASEB earlier in August. The company is developing GRI-0803 in autoimmune diseases, with an initial focus of systemic lupus erythematosus (SLE).
RSS
